The retinal tolerance to bevacizumab in co‐application with a recombinant tissue plasminogen activator

AIM: To investigate the retinal toxicity of bevacizumab in co‐application with a commercially available recombinant tissue plasminogen activator (rt‐PA), and to facilitate a new therapeutic concept in the treatment of massive subretinal haemorrhage caused by neovascular age‐related macular degenerat...

Descripció completa

Guardat en:
Dades bibliogràfiques
Autors principals: Lüke, Matthias, Januschowski, Kai, Warga, Max, Beutel, Julia, Leitritz, Martin, Gelisken, Faik, Grisanti, Salvatore, Schneider, Toni, Lüke, Christoph, Bartz‐Schmidt, Karl Ulrich, Szurman, Peter
Format: Artigo
Idioma:Inglês
Publicat: BMJ Group 2007
Matèries:
Laboratory Science - Extended Report
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC1954819/
https://ncbi.nlm.nih.gov/pubmed/17383998
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1136/bjo.2006.111260
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars